Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis

Abstract

Adenovirus type 5 E1A protein (E1A) associates with anti-tumor activities by reversing the transformed phenotype, inhibiting metastasis, and inducing apoptosis. We have previously identified that E1A suppresses the expression of Axl, a transforming tyrosine kinase and that Axl-Gas6 receptor-ligand interaction prevents E1A transfectants from apoptosis induced by serum deprivation. To determine how the Axl-Gas6 interaction prevents E1A-mediated apoptosis, we analysed the expression of anti-apoptotic molecules and found that the activated form of Akt was suppressed in the E1A transfectant ip 1-E1A and that Gas6 was able to activate Akt in ip 1-E1A cells reexpressing Axl (ip 1-E1A-Axl). To determine whether activated Akt is required to prevent E1A-mediated apoptosis, ip 1-E1A-Axl cells were treated with the phosphatidylinositol-3′-OH kinase inhibitor wortmannin or transfected with a dominant negative Akt mutant. In both cases, Gas6 no longer protected the cells from serum deprivation-induced apoptosis. Thus, we conclude that activated Akt is required for Axl-Gas6 signaling to prevent E1A-mediated apoptosis induced by serum deprivation. Downstream molecules of Akt, including NF-κB, Fas ligand, and BAD were examined, among which phosphorylation of BAD by Axl-Gas6 signaling is associated with the anti-apoptotic activity of Akt in our study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

Abbreviations

dnAkt:

dominant negative Akt

FACS:

fluorescence activated cell sorting

GFP:

green fluorescent protein

MAP kinase:

mitogen activated protein kinase

PI(3):

phosphatidylinositol 3′-phosphate

Wtmn:

Wortmannin

References

  • Bellosta P, Zhang Q, Goff SP, Basilico C . 1997 Oncogene 15: 2387–2397

  • Bellosta P, Costa M, Lin DA, Basilico C . 1995 Mol. Cell. Biol. 15: 614–625

  • Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME . 1999 Cell 96: 857–868

  • Burgering BM, Coffer PJ . 1995 Nature 376: 599–602

  • Byrd PJ, Grand RJA, Gallimore PH . 1988 Oncogene 2: 477–484

  • Chinnadurai G . 1992 Oncogene 7: 1255–1258

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME . 1997 Cell 91: 231–241

  • Debbas M, White E . 1993 Genes Dev. 7: 546–554

  • del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G . 1997 Science 278: 687–689

  • Deng J, Xia W, Hung M-C . 1998 Oncogene 17: 2167–2175

  • Douglas JL, Gopalakrishnan S, Quinlan MP . 1991 Oncogene 6: 2093–2103

  • Frisch SM . 2001 Adv. Cancer Res. 80: 39–49

  • Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN . 1995 Cell 81: 727–736

  • Fridell Y-W, Villa Jr J, Attar EC, Liu ET . 1998 J. Biol. Chem. 273: 7123–7126

  • Frisch SM . 1991 Proc. Natl. Acad. Sci. USA 88: 9077–9081

  • Frisch SM, Dolter KE . 1995 Cancer Res. 55: 5551–5555

  • Frisch SM, Reich R, Collier IE, Genrich LT, Martin G, Goldberg GI . 1990 Oncogene 5: 75–83

  • Goruppi S, Ruaro E, Varnum B, Schneider C . 1997 Mol. Cell. Biol. 17: 4442–4453

  • Goruppi S, Ruaro E, Schneider C . 1996 Oncogene 12: 471–480

  • Goruppi S, Ruaro E, Varnum B, Schneider C . 1999 Oncogene 18: 4224–4236

  • Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC . 2001 J. Clin. Oncol. 19: 3422–3433

  • Lamberti C, Williams J . 1990 J. Virol. 64: 4997–5007

  • Land H, Parada LF, Weinberg RA . 1983 Nature 304: 596–602

  • Lee W-P, Liao Y, Robinson D, Kung H-J, Liu ET, Hung M-C . 1999 Mol. Cell. Biol. 19: 8075–8082

  • Manfioletti G, Brancolini C, Avanzi G, Schneider C . 1993 Mol. Cell. Biol. 13: 4976–4985

  • Meier R, Alessi DR, Cron P, Andjelkovic M, Hemmings BA . 1997 J. Biol. Chem. 272: 30491–30497

  • Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ . 1998 J. Biol. Chem. 273: 200–206

  • Mymryk JS . 1996 Oncogene 13: 1581–1589

  • O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa III R, LeBeau MM, Earp HS, Liu ET . 1991 Mol. Cell. Biol. 11: 5016–5031

  • Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB . 1999 Nature 401: 82–85

  • Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E . 1992 Proc. Natl. Acad. Sci. USA 89: 7742–7746

  • Romashkova JA, Makarov SS . 1999 Nature 401: 86–90

  • Ruley HE . 1983 Nature 304: 602–606

  • Shalloway D, Johnson PJ, Freed EO, Coulter D, Flood Jr WA . 1987 Mol. Cell. Biol. 7: 3582–3590

  • Shao R, Hu MC-T, Zhou BP, Lin S-Y, von Lindern RH, Spohn B, Hung M-C . 1999 J. Biol. Chem. 274: 21495–21498

  • Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF, Masiakowski P, Ryan TE, Tobkes NJ, Chen DH, DiStefano PS, Long GL, Basillico C, Goldfarb MP, Lemke G, Glass DJ, Yancopoulos GD . 1995 Cell 80: 661–670

  • Towbin H, Staehelin T, Gordon J . 1979 Proc. Natl. Acad. Sci. USA 76: 4350–4354

  • Teodoro JG, Shore GC, Branton PE . 1995 Oncogene 11: 467–474

  • Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell Y-W, Hunt RW, Trail G, Clogston C, Toso RJ, Yanaglhara D, Bennett L, Sylber M, Merewether LA, Tseng A, Escobar E, Liu ET, Yamane HK . 1995 Nature 373: 623–626

  • Yan D-H, Chang L-S, Hung M-C . 1991 Oncogene 6: 343–345

  • Yu D, Hung M-C . 1998 Cancer Metastasis Rev. 17: 195–202

  • Yu D, Suen T-C, Yan D-H, Chang L-S, Hung M-C . 1990 Proc. Natl. Acad. Sci. USA 87: 4499–4503

  • Yu D, Scorsone K, Hung M-C . 1991 Mol. Cell. Biol. 11: 1745–1750

  • Yu D, Hamada J-H, Zhang H, Nicolson GL, Hung M-C . 1992 Oncogene 7: 2263–2270

  • Yu D, Martin A, Xia W, Sorgi F, Huang L, Hung M-C . 1995 Oncogene 11: 1383–1388

  • Yu D, Shi D, Scanlon M, Hung M-C . 1993a Cancer Res. 53: 5784–5790

  • Yu D, Wolf JK, Scanlon M, Price JE, Hung M-C . 1993b Cancer Res. 53: 891–898

  • Zhou BP, Hu MC-T, Miller S, Yu Z, Xia W, Lin S-Y, Hung M-C . 2000 J. Biol. Chem. 275: 8027–8031

  • Zimmermann S, Moelling K . 1999 Science 286: 1741–1744

Download references

Acknowledgements

This work was supported by NIH grants R01-CA 58880, R01-CA 77858, and SPORE in ovarian cancer 1 P50 CA 83639 (to M-C Hung).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mien-Chie Hung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, WP., Wen, Y., Varnum, B. et al. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21, 329–336 (2002). https://doi.org/10.1038/sj.onc.1205066

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205066

Keywords

This article is cited by

Search

Quick links